Table of Contents:

1 Report Prologue
2 Executive Summary
3 Market Introduction
3.1 Definition
3.2 Scope of the Study
3.3 List of Assumptions
3.4 Market Structure
4 Research Methodology
4.1 Research Process
4.2 Primary Research
4.3 Secondary Research
4.4 Market Size Estimation
4.5 Forecast Model
4.6 Introduction
4.7 Drivers
4.7.1 Increasing patient pool suffering from vitamin deficiency
4.7.2 Increasing demand for nutraceutical products containing vitamin K2
4.7.3 Increasing cases of osteoporosis
4.8 Restraints
4.8.1 Stringent regulations for nutraceuticals adversely affect the market
4.9 Opportunity
4.9.1 Multifunctional ingredients
5 Market Factor Analysis
5.1 Porter's Five Forces Model
5.1.1 Bargaining Power of Suppliers
5.1.2 Bargaining Power of Buyers
5.1.3 Threat of New Entrants
5.1.4 Threat of Substitutes
5.1.5 Rivalry
5.2 Supply Chain Analysis
5.2.1 Raw Material Planning & Procurement
5.2.1.1 Fermentation
5.2.1.2 Filtration
5.2.1.3 Extraction
5.2.1.4 Filtration Purification
5.2.2 Packaging
5.2.3 Transportation
5.2.4 Distribution Marketing & Sales
5.2.5 Post-sales Services
6 Global Vitamin K2 Market, by Product Type
6.1 Introduction
6.2 MK-7
6.3 MK-4
7 Global Vitamin K2 Market, by Source
7.1 Introduction
7.2 Natural
7.3 Synthetic
8 Global Vitamin K2 Market, by Form
8.1 Introduction
8.2 Powder
8.3 Oil
9 Global Vitamin K2 Market, by Application
9.1 Introduction
9.2 Nutraceutical and Food
9.3 Pharmaceutical
10 Global Vitamin K2 Market, by Region
10.1 Introduction
10.2 Americas
10.2.1 North America
10.2.1.1 US
10.2.1.2 Canada
10.2.2 Latin America
10.3 Europe
10.3.1 Western Europe
10.3.1.1 UK
10.3.1.2 Germany
10.3.1.3 France
10.3.1.4 Italy
10.3.1.5 Spain
10.3.1.6 Rest of Western Europe
10.3.2 Eastern Europe
10.4 Asia-Pacific
10.4.1 Australia
10.4.2 Japan
10.4.3 China
10.4.4 India
10.4.5 South Korea
10.4.6 Rest of Asia-Pacific
10.5 Middle East & Africa
10.5.1 Middle East
10.5.2 Africa
11 Competitive Landscape
11.1 Introduction
11.2 Company Market Share Analysis
12 Company Profiles
12.1 Kappa Bioscience
12.1.1 Company Overview
12.1.2 Financial Overview
12.1.3 Products/Services Offered
12.1.4 Key Developments
12.1.5 SWOT Analysis
12.1.6 Key Strategies
12.2 NattoPharma
12.2.1 Company Overview
12.2.2 Financial Overview
12.2.3 Products/Services Offered
12.2.4 Key Developments
12.2.5 SWOT Analysis
12.2.6 Key Strategies
12.3 Gnosis SpA
12.3.1 Company Overview
12.3.2 Financial Overview
12.3.3 Products/Services Offered
12.3.4 Key Developments
12.3.5 SWOT Analysis
12.3.6 Key Strategies
12.4 Viridis BioPharma
12.4.1 Company Overview
12.4.2 Financial Overview
12.4.3 Products/Services Offered
12.4.4 Key Developments
12.4.5 SWOT Analysis
12.4.6 Key Strategies
12.5 Seebio Biotech
12.5.1 Company Overview
12.5.2 Financial Overview
12.5.3 Products/Services Offered
12.5.4 Key Developments
12.5.5 SWOT Analysis
12.5.6 Key Strategies
12.6 DSM
12.6.1 Company Overview
12.6.2 Financial Overview
12.6.3 Products/Services Offered
12.6.4 Key Developments
12.6.5 SWOT Analysis
12.6.6 Key Strategies
12.7 Danisco A/S
12.7.1 Company Overview
12.7.2 Financial Overview
12.7.3 Products/Services Offered
12.7.4 Key Developments
12.7.5 SWOT Analysis
12.7.6 Key Strategies
12.8 Geneferm Biotechnology Co. Ltd
12.8.1 Company Overview
12.8.2 Financial Overview
12.8.3 Products/Services Offered
12.8.4 Key Developments
12.8.5 SWOT Analysis
12.8.6 Key Strategies
12.9 Frutarom
12.9.1 Company Overview
12.9.2 Financial Overview
12.9.3 Products/Services Offered
12.9.4 Key Developments
12.9.5 SWOT Analysis
12.9.6 Key Strategies
12.1 Kyowa Hakko Bio Co. Ltd
12.10.1 Company Overview
12.10.2 Financial Overview
12.10.3 Products/Services Offered
12.10.4 Key Developments
12.10.5 SWOT Analysis
12.10.6 Key Strategies
13 Appendix
13.1 Discussion Blueprint